

Prenylated Proteins. A Convenient Synthesis of Farnesyl Cysteinyll Thioethers

Mark J. Brown, Pamela D. Milano, David C. Lever, William W. Epstein, and C. Dale Poulter*

Department of Chemistry, University of Utah
Salt Lake City, Utah 84112


Received December 5, 1990

From recent discoveries it is abundantly clear that posttranslational modification of proteins with isoprene residues is an essential feature of several critical signal transduction systems in eukaryotic cells. The modifications occur at C-terminal cysteines and target the proteins to membranes.¹⁻⁵ C₁₅ farnesyl moieties were first discovered in yeast *a-factor* mating hormones⁶⁻⁸ and subsequently found in nuclear lamins,⁹ *ras*-encoded proteins,^{1,2,10,11} and the γ subunit of transducin, a retinal heterotrimeric G protein.¹² More recently, C₂₀ geranylgeranyl units were reported in γ subunits of rat¹³ and bovine¹⁴ G proteins. Geranylgeranylated proteins also appear to be the major prenylated species in HeLa¹⁵ and Chinese hamster ovary¹⁶ cells. The consensus sequence for prenylation is --Cys-Axx-Axx-Xxx (Axx, aliphatic amino acids; Xxx, general amino acids).^{1,4,5,17} Additional processing involves proteolytic removal of Axx-Axx-Xxx to generate a C-terminal thioether and, in some instances, methylation of the cysteinyl carboxylate.^{3,4,18} The *ras*-encoded proteins and heterotrimeric G proteins associate with the inner face of plasma membrane, where they form a biological link between membrane-spanning receptors and intracellular effectors. For human c-H-*ras*^{Val12} protein, inhibition of farnesylation results in cytosolic inactive protein.¹

In conjunction with their pioneering studies on yeast mating factors, Kamiya et al. synthesized *S*-farnesylcysteine and prenylated peptides by alkylation of the sulfhydryl groups with farnesyl bromide in alcohol/water mixtures.^{6,7,19} Recent discoveries of isoprene residues in signal transduction proteins have rekindled interest in the synthesis of cysteinyl thioethers.^{11,14-16,18} The modest yields of purified material we obtained with the Kamiya procedure, especially when the substrates were expensive peptides, prompted us to explore other conditions for the alkylation

of cysteine. This communication reports an improved synthesis of farnesyl cysteinyl thioethers.

A major problem in the prenylation of cysteine or peptides containing cysteinyl residues is the selection of a solvent that solubilizes the substrates without reacting with isoprenyl halides. We found liquid ammonia and 4 M ammonia in methanol to be suitable for small peptides and cysteine, respectively. In a typical reaction, 13 μ mol of the pentapeptide Lys-Cys-Val-Leu-Ser (KCVLS)²⁰ was dissolved in 5 mL of liquid ammonia, and 23 μ mol of farnesyl chloride²¹ was added. The mixture was refluxed for 2 h, solvent was allowed to evaporate, and the residue was dissolved in 5:50:1 MeCN/H₂O/HOAc. The solution was washed with



cysteine R¹ = H, R² = OH
cysteine methyl ester R¹ = H, R² = OCH₃
KCVLS R¹ = Lys, R² = Val-Leu-Ser

hexane, and solvent was removed at reduced pressure to give farnesylated KCVLS (>95%) as the sole peptide along with 1 equiv of ammonium chloride. For analytical purposes, residual salt was removed by HPLC on a Vydac C₁₈ reversed-phase column, although the material obtained after evaporation of solvent was suitable for use as standards in biological assays. FABMS showed an M + 1 peak at *m/z* 753, expected for addition of a single farnesyl residue. Comparisons of ¹H and ¹³C NMR²² spectra with those of *S*-farnesylcysteine and *S*-farnesylcysteine methyl ester (see below) indicated that alkylation occurred at the sulfhydryl moiety.²³ The absence of ¹³C peaks for diastereomers suggests that the reaction proceeded without racemization.

Although farnesylation of cysteine or cysteine methyl ester in liquid ammonia gave 40–60% yields, better results were obtained with an anhydrous 4 M solution of ammonia in methanol. In a standard experiment, 0.8 mmol of cysteine was allowed to react with 0.8 mmol of farnesyl chloride in 6 mL of ammonia/methanol at 0 °C for 3 h and 20 °C for 1 h. Solvent was removed at reduced pressure, and the residue was partitioned between 1-butanol and water. The butanol layer was dried over MgSO₄, and solvent was removed at reduced pressure. The residue was dissolved in methanol and washed with hexane. Evaporation of methanol gave a white waxy solid (*R_f* = 0.70; cellulose; 4:1 MeCN/H₂O), which was >95% pure as judged by HPLC (Vydac C₁₈; 50:50:0.1 MeCN/H₂O/TFA) and NMR spectroscopy, in 80% yield.²⁴ Cysteine methyl ester was farnesylated in 72% yield under similar conditions. In this case, the workup involved evaporation of solvent and partitioning of the residue into methyl *tert*-butyl ether (MTBE) and water. Chromatography of the extract on silica gel (*R_f* = 0.31, 0.1% triethylamine/MTBE) gave a pale yellow oil.²⁵

(20) KCVLS was prepared at the Utah Regional Cancer Center, which is supported by NIH Grant CA42014. The sequence was verified by Edman degradation and FABMS, *m/z* 549 (M + 1).

(21) Davisson, V. J.; Woodside, A. B.; Poulter, C. D. *Methods Enzymol.* **1985**, *110*, 130–144. We found that filtering a hexane solution of the product through a pad of silica gel removed colored impurities and gave better results in the farnesylation reaction.

(22) ¹³C NMR (75 MHz, 2:2:1 CD₃CN/D₂O/CD₃CO₂D): δ 174.1, 173.0, 172.8, 172.2, 169.7, 141.1, 136.2, 131.8, 125.0, 124.6, 120.0, 62.3, 60.2, 55.6, 54.1, 53.7, 52.8, 40.9, 40.2, 40.1, 40.0, 33.2, 31.4, 31.3, 30.3, 27.2, 26.9, 25.9, 25.3, 23.3, 22.2, 21.8, 19.4, 18.3, 17.8, 16.3, and 16.2 ppm.

(23) The C(1) farnesyl and β cysteinyl carbons were assigned to peaks at 30.3 \pm 0.2 and 33.5 \pm 0.2 ppm, respectively, in farnesylated cysteine and KCVLS. These assignments were based on a single frequency decoupling experiment with *S*-(dimethylallyl)cysteine, where irradiation at 2.73 ppm caused the ¹³C multiplet at 33.5 ppm to collapse to a singlet, while the signal at 30.3 ppm narrowed but remained a triplet. *S*-(Dimethylallyl)cysteine was prepared in 4 M NH₃/CH₃OH as described for the farnesyl derivative: ¹H NMR (300 MHz, CD₃OD) δ 1.62 (s, 3 H), 1.66 (s, 3 H), 2.73 (dd, 1 H, *J* = 9.1, 14.6 Hz), 3.05 (dd, 1 H, *J* = 3.8, 14.6 Hz), 3.16 (m, 2 H), 3.58 (dd, 1 H, *J* = 3.8, 9.1 Hz), and 5.18 (m, 1 H) ppm; ¹³C NMR (75 MHz, CD₃OD) δ 171.2, 137.0, 121.1, 55.2, 33.5, 30.3, 26.5, and 25.8 ppm.

(24) Mp: 143–146 °C dec (lit.⁶ mp 148–150 °C). ¹³C NMR (75 MHz, CD₃OD): δ 172.5, 140.9, 136.2, 132.0, 125.3, 125.0, 121.0, 55.2, 40.9, 40.8, 33.6, 30.3, 27.8, 27.5, 26.0, 17.8, 16.3, and 16.2 ppm.

- (1) Schafer, W. R.; Kim, R.; Sterne, R.; Thorner, J.; Kim, S.-H.; Rine, J. *Science* **1989**, *245*, 379–385.
- (2) Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. *Cell* **1989**, *57*, 1167–1177.
- (3) Glomset, J. A.; Gelb, M. H.; Farnsworth, C. D. *Trends Biochem. Sci.* **1990**, *15*, 137–142.
- (4) Goldstein, J. L.; Brown, M. *Nature (London)* **1990**, *343*, 425–430.
- (5) Schafer, W. R.; Trueblood, C. E.; Yang, C.-C.; Mayer, M. P.; Rosenberg, S.; Poulter, C. D.; Kim, S.-H.; Rine, J. *Science* **1990**, *249*, 1133–1139.
- (6) Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N.; Tsuchiya, E.; Abe, K.; Fukui, S. *Agric. Biol. Chem.* **1979**, *43*, 363–369.
- (7) Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N. *Agric. Biol. Chem.* **1979**, *43*, 1049–1053.
- (8) Anderegg, R. J.; Betz, R.; Carr, S. A.; Crabb, J. W.; Duntze, W. J. *Biol. Chem.* **1988**, *263*, 18236–18240.
- (9) Farnsworth, C. C.; Walda, S. L.; Gelb, M. H.; Glomset, J. A. *J. Biol. Chem.* **1989**, *264*, 20422–20429.
- (10) Casey, P. J.; Solski, P. A.; Der, C. J.; Buss, J. E. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 8323–8327.
- (11) Stimmel, J. B.; Deschenes, R. J.; Volker, C.; Stock, J.; Clarke, S. *Biochemistry* **1990**, *29*, 9651–9659.
- (12) Lai, R. K.; Perez-Sala, D.; Cañada, F. J.; Rando, R. R. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 7673–7677.
- (13) Mumby, S. M.; Casey, P. J.; Gilman, A. G.; Gutowski, S.; Sternweis, P. C. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 5873–5877.
- (14) Yamane, H. K.; Farnsworth, C. C.; Xie, H.; Howald, W.; Fung, B. K.-K.; Clarke, S.; Gelb, M. H.; Glomset, J. A. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 5868–5872.
- (15) Farnsworth, C. C.; Gelb, M. H.; Glomset, J. A. *Science* **1990**, *247*, 320–322.
- (16) Epstein, W. W.; Lever, D. C.; Rilling, H. C. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 7352–7354.
- (17) Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. *Cell* **1990**, *62*, 81–88.
- (18) Stephenson, R. C.; Clarke, S. *J. Biol. Chem.* **1990**, *265*, 16248–16254.
- (19) Kitada, C.; Fujino, M.; Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N.; Tsuchiya, E.; Abe, K.; Fukui, S. *Experientia* **1979**, *35*, 1275–1276.

Ammonia/methanol was also used as a solvent to farnesylate KCVLS; however, yields were lower and the peptide was less pure than for ammonia.

Du Vigneaud et al.²⁶ first described alkylation of cysteine in liquid ammonia. They generated the sodium thiolate by in situ reduction of cystine with sodium and then added electrophilic alkyl halides. We found cysteine to be readily alkylated by farnesyl chloride in ammonia by simply mixing the amino acid and the electrophile. The use of ammonia or methanol/ammonia²⁷ affords a mild regioselective procedure (note that KCVLS contains free amino, hydroxyl, and carboxylate moieties) for formation of farnesyl cysteinyl thioethers. We have used this procedure to construct farnesylated peptides needed for assays of protein prenyltransferase activity in yeast⁵ and as authentic samples for structure determinations of prenylated proteins.¹⁶ We are currently extending the study to other isoprene units and peptides.

Acknowledgment. This project was supported by NIH Grants GM21328 (C.D.P.) and DK 43055 (W.W.E.) and by NSF Grant DCB8803825 (W.W.E.).

(25) ¹³C NMR (75, MHz, CDCl₃): δ 168.4, 140.8, 135.3, 131.2, 124.2, 123.5, 118.7, 53.5, 52.4, 39.7, 39.7, 31.2, 29.5, 26.8, 26.5, 25.8, 17.8, 16.2, and 16.1 ppm.

(26) du Vigneaud, V.; Audrieth, L. F.; Loring, H. S. *J. Am. Chem. Soc.* **1930**, *52*, 4500.

(27) Ammonia/methanol was recently used as a solvent for alkylation of cysteine by nonallylic electrophiles. Or, Y. S.; Clark, R. F.; Luly, J. R. *J. Org. Chem.*, in press.

Efficient Method for Regioselective Isoprenylation of Cysteine Thiols in Unprotected Peptides

Chi-Ching Yang,* Charles K. Marlowe, and Robert Kania


Protos Corporation, 6455 Christie Avenue
Emeryville, California 94608

Received December 13, 1990

Isoprenylation, a recently discovered posttranslational modification of proteins,¹ has been found to be crucial for both membrane association and transforming activity of oncogenic *ras* proteins²⁻⁴ in which the isoprene unit is located at the C-terminal cysteine.^{5,6} The isoprene moiety on yeast *a*-factor mating hormone was identified unambiguously as the C₁₅ farnesyl group by ¹H NMR spectroscopy and mass spectrometry,⁷ and more recently, proteins of HeLa cells were reported to be geranylgeranylated (C₂₀ unit).⁸

The chemical synthesis of farnesylated peptides by alkylation of the sulphydryl group with farnesyl bromide in 50% DMF in the presence of MgO has been documented in the literature,^{9,10} however, we have had little success in preparing various isoprenylated peptides by the reported procedure. In this communi-

Scheme I



cation, we describe an improved and efficient method for regioselective isoprenylation of cysteine thiols in unprotected peptides.

The model system, cysteine methyl ester (**2**) containing an amino and a thiol nucleophile, in acetonitrile (ACN) and dimethylformamide (DMF) was treated with 4 equiv of farnesyl bromide¹¹ (**1**) (Scheme I) at 0 °C in the presence of diisopropylethylamine (DIEA). The resulting S-farnesylated cysteine methyl ester (**2_p**) (Scheme I), obtained in 90% yield, appeared as a single regioisomer by ¹H NMR analysis,¹² displaying the reported chemical shift for the C-1 allylic protons at 3.2 ppm.³ In addition, a positive quantitative ninhydrin result supports the structure of **2_p**. The farnesylation reaction was found to be very dependent on the quality of the farnesyl bromide,¹³ which is sensitive to decomposition upon silica gel purification and, therefore, was used directly without further purification.

Successful mono- and regioselective farnesylation of unprotected peptides with farnesyl bromide depends on the solvent system, temperature, pH, amount of the farnesyl bromide, and peptide concentration. Among various solvents,¹⁴ we have found that use of a mixed solvent system, DMSO/DMF/ACN, provided the maximal solubility for most peptides. Although several competing nucleophiles are present in the unprotected peptide, such as carboxylate anion, free amino group, phenolic anion, etc., we have found that farnesyl bromide reacts exclusively with the sulphydryl anion of the unprotected peptide at pH 10-12 at 0 °C to afford the desired S-alkylated adduct. The pH of the reaction mixture was maintained by addition of 6-9 equiv of DIEA (measured on moist pH paper). Three to four equivalents of farnesyl bromide with 0.01-0.02 M concentration of the peptide was found to represent optimal conditions. Use of greater amounts of farnesyl bromide (>10 equiv) and higher peptide concentrations (>0.06 M) often generate multifarnesylated adducts. The formation of the disulfide dimer was significantly suppressed by degassing of the reaction solution followed by sparging with argon.

In a typical reaction, the peptide (dansyl)WDPACVIA¹⁵ (**3**) (Scheme I) was treated with 3 equiv of farnesyl bromide in the mixed solvent DMSO/DMF/ACN (3:3:1) at a concentration of 0.01 M in the presence of 8 equiv of DIEA at 0 °C under an argon atmosphere for 3 h, to afford the desired S-farnesyl regioisomer (dansyl)WDPAC(far)VIA (**3_p**) (Scheme I), in 86% yield. The reaction mixture was quenched with acetic acid at 0 °C to bring the pH to around 4 and then lyophilized followed by reversed-phase (C₁₈) HPLC purification. The reaction is monitored by reversed-phase (C₁₈) HPLC with photodiode array detection¹⁶ from which the characteristic UV spectrum of each individual peak in the chromatogram is used to determine the progress of the reaction and to identify the mono- and multifarnesylated adducts. The structure of peptide **3_p** was characterized by amino acid analysis

(1) Rilling, H. C.; Breunger, W. W.; Epstein, P. E.; Crain, P. F. *Science* **1990**, *247*, 318.

(2) Schaffer, W. R.; Kim, R.; Sterne, R.; Thorner, J.; Kim, S.-H.; Rine, J. *Science* **1989**, *245*, 379.

(3) Jackson, J. H.; Cochrane, C. G.; Bourne, J. R.; Solski, P. A.; Buss, J. E.; Der, C. J. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 3042.

(4) Schaffer, W. R.; Trueblood, C. E.; Yang, C.-C.; Mayer, M. P.; Rosenberg, S.; Poulter, D.; Kim, S.-H.; Rine, J. *Science* **1990**, *249*, 1133.

(5) Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. *Cell* **1989**, *57*, 1167.

(6) Holbrook, S. R.; Kim, S.-H. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 1751.

(7) Anderson, R. J.; Betz, R.; Carr, S. A.; Crabb, J. W.; Duntze, W. J. *Biol. Chem.* **1988**, *263*, 1836.

(8) Farnsworth, C. C.; Gelb, M. H.; Glomset, J. A. *Science* **1990**, *247*, 320.

(9) Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N.; Abe, K.; Tsuchiya, E.; Fukui, S. *Agric. Biol. Chem.* **1979**, *43*, 363.

(10) Kitada, C.; Fujino, M.; Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N.; Abe, K.; Tsuchiya, E.; Fukui, S. *Experientia* **1979**, *35*, 1275.

(11) Baba, T.; Allen, C. M. *Biochemistry* **1978**, *17*, 5598.

(12) ¹H NMR spectral data of **2_p** (400 MHz, CDCl₃): δ 1.6 (s, 6 H), 1.67-1.68 (t, 6 H), 1.83-2.13 (m, 8 H), 2.28 (br, 2 H), 2.67 (dd, 1 H), 2.89 (dd, 1 H), 3.18 (m, 2 H), 3.63 (dd, 1 H), 3.74 (s, 3 H), 5.10 (m, 2 H), 5.23 (t, 1 H).

(13) Farnesyl bromide is stable at -20 °C for several months.

(14) Narita, M.; Umeyama, H.; Sasaki, C. *Int. J. Pept. Protein Res.* **1989**, *33*, 340. Seebach, D.; Thaler, A.; Beck, A. K. *Helv. Chim. Acta* **1989**, *72*, 857. Hendrix, J. C.; Halverson, K. J.; Jarrett, J. J.; Lansbury, P. T., Jr. *J. Org. Chem.* **1990**, *55*, 4517.

(15) All peptides were synthesized by using an ABI 401A synthesizer with standard *t*-Boc or Fmoc chemistry followed by acid cleavage. The crude peptides were purified by reversed-phase (C₁₈) HPLC. The peptides were characterized by amino acid analysis and fast atom bombardment mass spectroscopy.

(16) Young, P. M.; Burgoyne, R. F.; Wheat, T. E. *Pept. Res.* **1990**, *3*, 81.